Genetic Predisposition to Bleeding during Oral Anticoagulant Therapy: Evidence for Common Founder Mutations (FIXVal-10 and FIXThr-10) and an Independent CpG Hotspot Mutation (FIXThr-10)

Summary

The recent discovery of five patients with coumarin sensitive FIX-variants due to a missense mutation in the FIX propeptide, either Ala-10Val or Ala-10Thr, has highlighted a novel type of genetic predisposition to bleeding during oral anticoagulant therapy (OAT). In the present study, we report six additional patients with such FIX variants. Haplotype analysis of FIX polymorphisms revealed a founder effect in the five German and Swiss patients with the Val-10 variant. Also, four Thr-10 variants detected in Germany, Switzerland and Great Britain derived from a common founder. Two Thr-10 variants from USA showed an independent de novo origin at a CpG dinucleotide that in general represents a mutation hotspot. These findings implicate the existence of additional subjects with corresponding variants in the populations of various countries. Even though the rare occurrence of these variants does not justify a general aPTT screening during OAT, it is recommended to monitor each bleeding event during OAT in males in order to exclude a genetic predisposition to bleeding by means of the following testing strategy: a) aPTT-testing in each bleeding complication of male patients during OAT, b) if aPTT is disproportionately prolonged, determination of FIX:C, and c) if FIX:C is disproportionately decreased as compared to FII:C, FVII:C and FX:C, sequencing of exon 2 of the FIX gene. This strategy will provide a cost-effective and safe procedure to identify patients that carry the FIX variants. Moreover, such a strategy accumulates data about the prevalence of these FIX mutations in a given population.

Keywords

Factor IX gene - warfarin sensitivity - oral anticoagulation - founder effect

• References

• 1 Hull R, Hirsh J, Jay R. et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
• 2 Palareti G, Leali N, Coccheri S. et al. Bleeding complications during oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
• 3 Chu K, Wu SM, Stanley T, Stafford DW, High KA. A mutation in the pro-peptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996; 98: 1619-25.
• 4 Oldenburg J, Quenzel EM, Harbrecht U. et al. Missense mutation at Ala-10 in the factor IX-propeptide: an insignificant variant in normal life but a decisive cause for bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-4.
• 5 Baker P, Clarke K, Giangrande P, Keeling D. Ala-10 mutations in the factor IX propeptide and haemorrhage in a patient treated with warfarin. Br J Haematol 2000; 108: 663.
• 6 Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie B. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 1987; 48: 185-91.
• 7 Rabiet MJ, Jorgensen MJ, Furie B, Furie BC. Effect of the propeptide mutations on post-translational processing of factor IX. J Biol Chem 1987; 265: 13124-9.
• 8 Stanley TB, Humphries J, High KA, Stafford DW. Amino acids responsible for reduced affinities of vitamin K-dependent propeptides of the carboxylase. Biochemistry 1999; 38: 15681-7.
• 9 Quenzel EM, Hertfelder HJ, Oldenburg J. Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy. Ann of Hematol 1997; 74: 265-8.
• 10 Peters J, Luddington R, Brown K, Baglin C, Baglin T. Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide. Br J Haematol 1997; 99: 467-8.
• 11 van der Meer FJ, Vos HL, Rosendaal FR. No indication for aPTT screening in patients on oral anticoagulant therapy. Thromb Haemost 1999; 81: 364-6.
• 12 Harbrecht U, Oldenburg J, Klein P, Weber D, Rockstroh J, Hanfland P. Increased sensitivity of factor IX to phenprocoumon as a cause of bleeding in a patient with antiphospholipid antibody associated thrombosis. J Int Med 1998; 243: 73-7.
• 13 Winship PR, Peake IR. A clinically useful RFLP in the 5′flanking region of the factor IX gene. Br J Haematol 1992; 80: 26a (abstract).
• 14 Winship PR, Anson DS, Rizza CR, Brownlee GG. Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphism. Nucleic Acids Res 1984; 12: 8861-72.
• 15 Gianelli F, Choo KH, Winship PR. Characterization and use of an intragenic polymorphic marker for detection of carriers of haemophilia B (factor IX deficiency). Lancet 1984; I: 239-41.
• 16 Winship PR, Rees DJG, Alkan M. Detection of polymorphisms at cytosine phosphoguanodine dinucleotides and diagnosis of Haemophilia B carriers. Lancet 1989; I: 631-4.
• 17 Peake IR, Lillicrap DP, Boulyjenkov V. et al. Report of a joint WHO/WFH meeting on the control of haemophilia: carrier detection and prenatal diagnosis. Blood Coagulation and Fibrinolysis 1993; 4: 313-44.
• 18 Lehesjoki AE, Rasi V, Chapelle de la A. Hemophilia B: Diagnostic value of RFLP analysis in 19 of the 20 known Finnish families. Clinical Genetics 1990; 38: 187-97.
• 19 Bowen DJ, Thomas P, Webb CE, Bignell P, Peake IR, Bloom AL. Facile and rapid analysis of three DNA polymorphisms within the human factor IX gene using the polymerase chain reaction. Br J Haematol 1991; 77: 559-60.
• 20 Grimm J, Grimm W. Deutsches Wörterbuch. Neunter Band. Verlag von S. Hirzel. 1899; 2472-3.
• 21 Cooper DN, Youssouffian H. The CpG dinucleotide and human genetic disease. Human Genetics 1988; 78: 151-5.